Invivyd To Participate In Upcoming Investor Events
2026 Jefferies Global Healthcare Conference in New York
Fireside Chat Date & Time: Wednesday, June 3, 2026 4:55 p.m. ET
Location: New York, NY
Webcast Link
H.C. Wainwright“HCW @ Home” Series
Fireside Chat Date & Time: Monday, June 8, 2026 10:00 a.m. ET
Location: Virtual
Webcast Link
BTIG Infectious D isease D ay 2026
Date: Tuesday, June 16, 2026
1x1 Meetings
Location: Virtual
Live webcasts of the fireside chats will be available in the investor section of the company's website at invivyd and will be archived following each event.
The management team will host investor meetings at the Jeffries Conference, following the H.C. Wainwright Virtual Fireside Chat, and as part of the BTIG Infectious Disease Day 2026. Investors participating in these events who are interested in meeting with Invivyd management should contact their Jeffries, H.C. Wainwright, or BTIG representatives.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit to learn more.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-0160
...
Investor Relations
(781) 208-1747
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment